Fundraising Fox
/Companies
Sign in

Liberate Bio

Founded 2022 · 14 employees on LinkedIn · 1 known investors

Find your way into Liberate Bio

Sign up to see every warm intro you have to Liberate Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Liberate Bio team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.

BiotechDeep TechDigital HealthMedical Devices

Founders & leadership

Liberate Bio was founded in 2022 by Nessan Bermingham, PhD, Theresa M. Reineke, PhD, and Michael Mitchell, PhD.

NB
Nessan Bermingham, PhDCo-founder, Khosla Ventures
TM
Theresa M. Reineke, PhDCo-founder, University of Minnesota
MM
Michael Mitchell, PhDCo-founder, University of Pennsylvania
WSWalter Strapps
Walter StrappsChief Scientific Officer
SDShawn Davis, PhD
Shawn Davis, PhDCEO
MM
Michael MitchellFounder
NB
Nessan BerminghamFounder
SS
Stephen ScullyFounder
TR
Theresa ReinekeFounder

Investors · 1

Related companies · 2

elevatebioElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing. It partners with drug developers to bring cell and gene therapies from early discovery through commercial-scale cGMP manufacturing.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as Liberate Bio.

In the news

Liberate Bio Presents New Preclinical Data Supporting First Clinical Evaluation of In Vivo CAR-M Program LIB820 in Autoimmune Disease - BioSpacebiospace.com · May 2026

Frequently asked questions

What does Liberate Bio do?
Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
Who founded Liberate Bio?
Liberate Bio was founded by Nessan Bermingham, PhD, Theresa M. Reineke, PhD, Michael Mitchell, PhD in 2022.
Who are Liberate Bio's investors?
Liberate Bio's investors include Khosla Ventures.